RCM Accretive Health

R1 Announces Appointment of Jill Smith to Board of Directors

R1 Announces Appointment of Jill Smith to Board of Directors

Charles Ditkoff Announces Decision to Retire from Board at Annual Meeting

CHICAGO, April 16, 2019 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced the appointment of Jill Smith, CEO of Allied Minds (LSE: ALM), to the company’s Board of Directors, effective April 12, 2019.

“We are very pleased to welcome Jill to R1’s Board of Directors,” said Alex Mandl, Lead Director of R1’s Board. “Jill has been successful in growing and transforming companies with technology-enabled services at the core of that experience. I believe these experiences combined with her leadership and strategy acumen will make Jill a great addition to our Board.”

Jill Smith currently serves as CEO of Allied Minds (LSE: ALM). She brings more than 25 years of experience as an international business leader, having served as CEO of private and public companies in the technology and information services markets. Jill previously served as Chairman, Chief Executive Officer and President of DigitalGlobe Inc., a global provider of satellite imagery products and services, including through its successful IPO in 2009; President and CEO of eDial, a voice-over IP collaboration company, from start-up to sale of the business to Alcatel in 2004; COO of Micron Electronics, a PC manufacturer; founder and Managing Partner of Treacy & Company, a strategy consulting and boutique investment firm; and President and CEO of SRDS, a media information and publishing company. Jill began her career as a consultant at Bain & Company in London and Boston, where she became a Partner.

The Company also announced that Charles Ditkoff has decided to retire from the Board at the company’s next annual meeting in June 2019 and will not stand for re-election. “I have been honored to serve on the R1 Board and am immensely proud of all that the R1 team accomplished in the past several years. I leave confident in the strategy and direction of the Company, knowing that it is in good hands with this management team,” said Ditkoff.

“On behalf of the Board and our management team, I’d like to thank Charlie for contributing his expertise and sound judgment to the Board as we navigated times of great opportunity and challenge, and for serving as a valuable resource to the R1 management team,” said Joe Flanagan, President and CEO of R1. “Charlie played a key role at many critical junctures, and we appreciate all that he has done for R1 and our shareholders.”

About R1 RCM

R1 is a leading provider of technology-enabled revenue cycle management services which transform a health system’s revenue cycle performance across settings of care. R1’s proven and scalable operating model, the R1 Performance Stack℠, seamlessly complements a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more visit: R1RCM.com

Contact:

R1 RCM Inc.

Investor Relations:

Atif Rahim

312-324-5476

Media Relations:

Brenda Stewart

312-255-7786

EN
16/04/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Accretive Health

 PRESS RELEASE

TowerBrook and CD&R Complete Acquisition of R1 RCM

TowerBrook and CD&R Complete Acquisition of R1 RCM R1 RCM Becomes Privately Held Company; Joe Flanagan Reappointed as CEO MURRAY, Utah, Nov. 19, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (“R1”), a leader in automating revenue management for healthcare providers, today announced that investment funds affiliated with TowerBrook Capital Partners (“TowerBrook”) and Clayton, Dubilier & Rice (“CD&R”) have completed their previously announced acquisition of R1. On August 1, 2024, TowerBrook, CD&R and R1 announced that they had entered into a definitive merger agreement under which all outstanding ...

 PRESS RELEASE

R1 RCM Reports Third Quarter 2024 Results

R1 RCM Reports Third Quarter 2024 Results MURRAY, Utah, Nov. 05, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2024. Third Quarter 2024 Results: Revenue of $656.8 million, up $84.0 million or 14.7% compared to the same period last year.GAAP net loss of $19.9 million, compared to net income of $1.3 million in the same period last year.Adjusted EBITDA of $148...

 PRESS RELEASE

R1 RCM Reports Second Quarter 2024 Results

R1 RCM Reports Second Quarter 2024 Results MURRAY, Utah, Aug. 07, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended June 30, 2024. Second Quarter 2024 Results: Revenue of $627.9 million, up $67.2 million or 12.0% compared to the same period last year.GAAP net loss of $7.6 million, compared to net loss of $1.0 million in the same period las...

 PRESS RELEASE

R1 RCM to be Acquired by TowerBrook and CD&R for $8.9 Billion

R1 RCM to be Acquired by TowerBrook and CD&R for $8.9 Billion Stockholders to Receive $14.30 Per Share in Cash MURRAY, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has entered into a definitive agreement to be acquired by investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice (“CD&R”), in an all-cash transaction with an enterprise value of approxi...

 PRESS RELEASE

R1 RCM Special Committee Provides Update on Evaluation of Strategic Al...

R1 RCM Special Committee Provides Update on Evaluation of Strategic Alternatives Sets Final Bid Deadline of July 31, 2024 MURRAY, Utah, July 24, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”) Board of Directors, which comprises independent directors and was formed to evaluate strategic alternatives in response to the Schedule 13D/A filed by New Mountain Capital, L.L.C. (“New Mountain Capital”) with the Securities and Exchange Commission on February 26, 2024, today announced it has set a final deadline for interested parties to sub...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch